01/09/15 - 10:42 AM EST
The 2015 biotech stock predictions of TheStreet contributor David Sobek.
12/18/14 - 09:35 AM EST
Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.
11/19/14 - 11:17 AM EST
Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.
11/05/14 - 08:00 AM EST
The diversification away from Xtandi has only just begun.
10/15/14 - 09:35 AM EDT
Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.
10/02/14 - 09:21 AM EDT
An Acceleron update in December could reignite investor interest in the stock.
09/17/14 - 08:26 AM EDT
The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.
09/10/14 - 09:36 AM EDT
The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)
09/03/14 - 06:30 AM EDT
Tetraphase is on track to begin second portion of pivotal study in the fourth quarter.
08/27/14 - 08:00 AM EDT
Tetraphase will report data from a phase III study of eravacycline in which the experimental antibiotic is first given by intravenous infusion and then transitioned to an oral form.